X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs WOCKHARDT LTD. - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

WOCKHARDT LTD. 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD WOCKHARDT LTD. BIOCON LTD/
WOCKHARDT LTD.
 
P/E (TTM) x 96.7 -21.6 - View Chart
P/BV x 8.2 2.2 374.1% View Chart
Dividend Yield % 0.1 0.0 8,023.2%  

Financials

 BIOCON LTD   WOCKHARDT LTD.
EQUITY SHARE DATA
    BIOCON LTD
Mar-18
WOCKHARDT LTD.
Mar-18
BIOCON LTD/
WOCKHARDT LTD.
5-Yr Chart
Click to enlarge
High Rs1,1881,012 117.4%   
Low Rs305532 57.4%   
Sales per share (Unadj.) Rs68.7355.9 19.3%  
Earnings per share (Unadj.) Rs7.6-60.3 -12.5%  
Cash flow per share (Unadj.) Rs14.0-46.8 -29.9%  
Dividends per share (Unadj.) Rs1.000.01 10,000.0%  
Dividend yield (eoy) %0.10 10,338.2%  
Book value per share (Unadj.) Rs86.3257.8 33.5%  
Shares outstanding (eoy) m600.00110.63 542.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.92.2 500.9%   
Avg P/E ratio x98.9-12.8 -772.1%  
P/CF ratio (eoy) x53.4-16.5 -323.8%  
Price / Book Value ratio x8.63.0 288.8%  
Dividend payout %13.20 -79,820.1%   
Avg Mkt Cap Rs m447,90085,379 524.6%   
No. of employees `0006.16.3 98.3%   
Total wages/salary Rs m9,3119,371 99.4%   
Avg. sales/employee Rs Th6,705.86,295.0 106.5%   
Avg. wages/employee Rs Th1,514.21,498.3 101.1%   
Avg. net profit/employee Rs Th736.9-1,066.3 -69.1%   
INCOME DATA
Net Sales Rs m41,23439,369 104.7%  
Other income Rs m2,0621,202 171.5%   
Total revenues Rs m43,29640,571 106.7%   
Gross profit Rs m8,29118 45,306.0%  
Depreciation Rs m3,8511,495 257.5%   
Interest Rs m6152,555 24.1%   
Profit before tax Rs m5,887-2,830 -208.1%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-3,582 0.0%   
Tax Rs m1,569257 610.5%   
Profit after tax Rs m4,531-6,669 -67.9%  
Gross profit margin %20.10 43,256.8%  
Effective tax rate %26.7-9.1 -293.4%   
Net profit margin %11.0-16.9 -64.9%  
BALANCE SHEET DATA
Current assets Rs m41,48633,796 122.8%   
Current liabilities Rs m21,41326,917 79.6%   
Net working cap to sales %48.717.5 278.6%  
Current ratio x1.91.3 154.3%  
Inventory Days Days6479 80.6%  
Debtors Days Days9489 105.5%  
Net fixed assets Rs m50,66139,664 127.7%   
Share capital Rs m3,000553 542.3%   
"Free" reserves Rs m48,80827,968 174.5%   
Net worth Rs m51,80828,522 181.6%   
Long term debt Rs m17,89821,731 82.4%   
Total assets Rs m99,89781,620 122.4%  
Interest coverage x10.6-0.1 -9,833.0%   
Debt to equity ratio x0.30.8 45.3%  
Sales to assets ratio x0.40.5 85.6%   
Return on assets %5.2-5.0 -102.2%  
Return on equity %8.7-23.4 -37.4%  
Return on capital %9.6-7.7 -125.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,0589,807 123.0%   
Fx outflow Rs m7,3481,789 410.8%   
Net fx Rs m4,7108,019 58.7%   
CASH FLOW
From Operations Rs m6,621684 967.4%  
From Investments Rs m-6,8406,302 -108.5%  
From Financial Activity Rs m-2,397-7,695 31.2%  
Net Cashflow Rs m-2,612-664 393.4%  

Share Holding

Indian Promoters % 40.4 74.5 54.2%  
Foreign collaborators % 20.6 0.0 -  
Indian inst/Mut Fund % 8.4 2.3 365.2%  
FIIs % 10.7 7.7 139.0%  
ADR/GDR % 0.0 0.1 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 67,757 162.3%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   VENUS REMEDIES  ORCHID PHARMA LTD  SANOFI INDIA  J.B.CHEMICALS  MERCK LTD  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Related Views on News

BIOCON LTD Surges by 5%; BSE HEALTHCARE Index Up 1.8% (Market Updates)

Sep 25, 2018 | Updated on Sep 25, 2018

BIOCON LTD share price has surged by 5% and its current market price is Rs 701. The BSE HEALTHCARE is up by 1.8%. The top gainers in the BSE HEALTHCARE Index is BIOCON LTD (up 5.0%). The top losers are ABBOTT INDIA and J.B.CHEMICALS (down 0.3%).

WOCKHARDT LTD. Announces Quarterly Results (1QFY19); Net Profit Down 81.4% (Quarterly Result Update)

Aug 6, 2018 | Updated on Aug 6, 2018

For the quarter ended June 2018, WOCKHARDT LTD. has posted a net profit of Rs 862 m (down 81.4% YoY). Sales on the other hand came in at Rs 10 bn (up 13.1% YoY). Read on for a complete analysis of WOCKHARDT LTD.'s quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

How IL&FS Rating Downgrade Will Impact Your Mutual Funds...(Outside View)

Sep 17, 2018

PersonalFN explains the impact of IL&FS rating downgrade on mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Sep 25, 2018 03:37 PM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

BIOCON LTD 8-QTR ANALYSIS

COMPARE BIOCON LTD WITH

MARKET STATS